PAGE 1 OF 4 PAGES
Amendment No. 35
Corrected Copy

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

and orders of the Nuclear Regulato	ry Commission now or hereafter in	effect and to any conditions specified below.	
Licer  1. Galen Hospital Alaska, Industrial Hospital Hosp	nc.	In accordance with letter dated April 11, 2017	4. Expiration Date: January 31, 2026
2. P.O. Box 143889 Anchorage, AK 99514-3	JC'	License number: 50-18244-01 is amended in its entirety to read as follows:	5. Docket No.: 030-14720 Reference No.:
Byproduct, source,     and/or special nuclear     material	7. Chemical and/or physical for	8. Maximum amount that license may possess at any one time under this license	
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As Needed	<ul> <li>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</li> </ul>
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 1.5 curies total	C. For any use permitted by 10 CFR 35.300.
D. Cesium-137 permitted by 10 CFR 35.400	D. Sealed Sources (Medi-Phy Inc. dba GE Healthcare (for Amersham), Model CDC.1 Series tube source))	ormerly	D. For any manual brachytherapy procedure permitted by 10 CFR 35.400.

NRC FORM 374A		U.S. NUCLE	AR REGULATORY COMM	ISSION		PAGE 2 OF 4 PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 50-18244-01		Docket or Referen	ce Number	
		Amendment No. 35 (Corrected Copy)	i			
Byproduct, source,     and/or special nuclear     material	7. Chemical and/o	or physical form	Maximum amou     may possess a     under this licen	t any one time	9. Autho	rized use
E. lodine-125 permitted by 10 CFR 35.400	Series; IsoAid IAI-125A; The	y, Inc., Model st Medical Inc., Model 2300 I, LLC, Model	E. 30 millicuries	total		iny manual brachytherapy edure permitted by 10 CFR 35.400.
F. Palladium-103 permitted by 10 CFR 35.400	F. Sealed Source International, Series; IsoAid IAPd-103A; T Corporation, N	Inc, Model 2300 , LLC, Model heragenics	F. 30 millicuries	total O		ny manual brachytherapy edure permitted by 10 CFR 35.400.
G. Strontium-90 permitted by 10 CFR 35.400		es (GE Healthcare ersham), Model	G. 90 millicuries	total		torage only. The medical use of sealed source is not authorized.
CONDITIONS						
10. Licensed material shall be used or stored only at the licensee's facilities located at 2801 De Barr Road, Anchorage, Alaska.						

- 11. The Radiation Safety Officer (RSO) for this license is Peter A. Stokinger.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	IISSION	PAGE 3 OF 4 PAGES
MATERIALS LICENSE	License Number 50-18244-01	Docket or Reference Number 030-14720	
SUPPLEMENTARY SHEET	Amendment No. 35		
	(Corrected Copy)		

B. The following individuals are authorized users for the material and medical uses indicated:

Authorized User(M.D.,D.O.,etc.)	Material and Use
Bradley K. Cruz, M.D.	35.100; 35.200; 35.300 <b>G</b>
Lester B. Lewis, M.D.	35.100; 35.200; 35.300
Glenn R. Stewart, M.D.	35.300; 35.400
Richard Chung, M.D.	35.300; 35.400
Lawrence P. Wood, M.D.	35.100; 35.200; oral administration of sodium iodide I-131
Julee K. Holayter, M.D.	35.100; 35.200; 35.300
David Mills, M.D.	35.100; 35.200
Andrew Moran, M.D.	35.100; 35.200
Mark G. Poag, M.D.	35.100; 35.200; 35.300

- 13. The licensee shall conduct a physical inventory every 6 months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sealed sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 3 years from the date of each inventory, and shall include the radionuclides, quantities, manufacturer's name and model numbers, and the date of the inventory.
- 14. Sealed sources and detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
- 15. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMI	SSION PAGE 4 OF 4 PAGES	
MATERIALS LICENSE	License Number 50-18244-01	Docket or Reference Number 030-14720	
SUPPLEMENTARY SHEET	Amendment No. 35		
	(Corrected Copy)		
<ul> <li>16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.</li> <li>A. Application dated January 31, 2005 (ML050470499)</li> <li>B. Letter dated September 26, 2006 (ML070250358)</li> <li>C. Letter dated August 28, 2007 (ML072820029)</li> <li>D. Letter dated August 29, 2010 (ML102710598)</li> <li>E. Letter dated December 8, 2016 with enclosures (ML17100A950)</li> <li>G. E-mail dated April 11, 2017 with enclosures (ML17102B285)</li> </ul>			
Date:April 12, 2017	Ву: _	/RA/	
		oberto J. Torres egion IV	